The Endeavor Story

With advances in next-generation sequencing and molecular profiling, we now have the tools to uncover the genetic culprits of disease. We can go after targets and indications we were not scientifically capable of investigating in the past. And we can finally bring patients best-in-class medicines across a spectrum of indications that target the core drivers of disease – making a significant impact even in terminal conditions.

At Endeavor BioMedicines, they are pursuing novel science and developing precision medicines. They combine advancements in technology with insights into the causes of disease to develop best-in-class medicines with the potential to treat the most severe health conditions, including cancer and fibrosis.

Featuring John Hood, CEO Endeavor Biomediomedicines with Dr. Jason Luke, UPMC and hosted by Montel Williams & Olga Villaverde.

Potentially find your optimal treatment plan by identifying your specific cancer mutations through NGS testing. Every patient should get NGS testing done to understand what may be causing their cancer.

This is a simple procedure that requires blood work or a tissue sample. A specialized lab analyzes these samples to fully sequence a large variety of mutations in your body. NGS testing is often encouraged in advanced cancer patients, and it represents a crucial step in delivering personalized medicines to patients.

Endeavor is partnered with xCures, a company that enables patients to find suitable treatment options. Endeavor is currently looking for patients with the PTCH1-Loss of Function (LOF) mutation. Regardless of your eligibility for the Endeavor Trial, xCures will send you a list of other treatment options that could work for your cancer mutation. This means that even if you do not qualify for the Endeavor trial, you will receive a list of other treatment options that could work against your cancer mutation.

ENV-101 is a small molecule that potently inhibits the Hedgehog pathway. When abnormally activated, this pathway is associated with growth and progression of cancer. Normally, PTCH-1 keeps the Hedgehog pathway “off,” so when mutations occur in PTCH-1 that affect its function, the pathway can become highly activated and may become a key driver in those cancers.

Six clinical studies have characterized ENV-101, demonstrating that the molecule may be effective in some cancers and has a manageable safety profile.